2016 ACR/ARHP Annual Meeting

November 11-16, 2016. Washington, DC.

View by Number View by Title View Sessions

View by Date

Tuesday, November 15, 2016

9:00AM-11:00AM: Abstract Number: 2852

Long Term Prognosis of Lupus Nephritis in the Afro-Caribbean Population of Martinique with Free Access to Healthcare

Systemic Lupus Erythematosus – Clinical Aspects and Treatment - Poster III: Biomarkers and Nephritis

9:00AM-11:00AM: Abstract Number: 2517

Long-Term Stability of the 5-Item Compliance Questionnaire Rheumatology As a Measure of Adherence in Patients with Rheumatoid Arthritis

Rheumatoid Arthritis – Clinical Aspects - Poster III: Treatment – Monitoring, Outcomes, Adverse Events

9:00AM-11:00AM: Abstract Number: 2835

Longitudinal Analysis of Th1 and Th2 Cytokines in Systemic Lupus Erythematosus

Systemic Lupus Erythematosus – Clinical Aspects and Treatment - Poster III: Biomarkers and Nephritis

9:00AM-11:00AM: Abstract Number: 2349

Longitudinal Construct Validity for Four Patient-Reported Outcomes Measurement Information System (PROMIS) Short Forms: Physical Function, Pain Interference, Depression, and Anxiety Among Adults with Knee Osteoarthritis

Osteoarthritis – Clinical Aspects - Poster II

9:00AM-11:00AM: Abstract Number: 2511

Longitudinal Observation of Disease Activity and Treatment of Rheumatoid Arthritis Who Developed Methotrexate-Associated Lymphoproliferative Disorders

Rheumatoid Arthritis – Clinical Aspects - Poster III: Treatment – Monitoring, Outcomes, Adverse Events

9:00AM-11:00AM: Abstract Number: 2833

Low Plasma Concentrations of Apolipoprotein M Correlate to Disease Activity and Endothelial Dysfunction in SLE

Systemic Lupus Erythematosus – Clinical Aspects and Treatment - Poster III: Biomarkers and Nephritis

9:00AM-11:00AM: Abstract Number: 2796

Low Versus High Dose Glucocorticosteroid Used in Lupus Nephritis: Is There a Difference

Systemic Lupus Erythematosus – Clinical Aspects and Treatment - Poster III: Biomarkers and Nephritis

9:00AM-11:00AM: Abstract Number: 13L

Low-Dose IL-2 Therapy in Refractory SLE: Results from Single Center Phase I/IIa Clinical Trial

ACR Late-Breaking Poster Session

9:00AM-11:00AM: Abstract Number: 2521

Lower Baseline 14-3-3η Levels Are Associated with Better Patient Reported Outcomes in Tocilizumab Treated Patients

Rheumatoid Arthritis – Clinical Aspects - Poster III: Treatment – Monitoring, Outcomes, Adverse Events

9:00AM-11:00AM: Abstract Number: 2866

Lupus HDL Induces Pro-Inflammatory Responses in Macrophages By Binding LOX1Rand Failing to Promote ATF3 Activity

Systemic Lupus Erythematosus – Human Etiology and Pathogenesis - Poster II

9:00AM-11:00AM: Abstract Number: 2513

Maintained Remission in Rheumatoid Arthritis over 7 Years in «Real Life Conditions» : A Monocentric Observational Study

Rheumatoid Arthritis – Clinical Aspects - Poster III: Treatment – Monitoring, Outcomes, Adverse Events

9:00AM-11:00AM: Abstract Number: 2124

Maintenance of Chondrocyte Phenotypic Stability By TRPC6 Calcium Channel Activity

Biology and Pathology of Bone and Joint - Poster I

9:00AM-11:00AM: Abstract Number: 2878

Major Lymphocyte Populations Share a Common Interferon Signature but Express Cell Type-Specific Interferon Pathway Genes in SLE

Systemic Lupus Erythematosus – Human Etiology and Pathogenesis - Poster II

9:00AM-11:00AM: Abstract Number: 2503

Making Room for RA Patient Symptoms into Treatment Decision: A Physician Perspective Study

Rheumatoid Arthritis – Clinical Aspects - Poster III: Treatment – Monitoring, Outcomes, Adverse Events

9:00AM-11:00AM: Abstract Number: 2305

Mapping the Topography of Gout Flares: Solutions for Flare Reporting in Gout Clinical Trials

Metabolic and Crystal Arthropathies - Poster II: Epidemiology and Mechanisms of Disease

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].